Table 3 Patient demographics
N (%) | BI 2 mg QD (n = 123) | BI 5 mg QD (n = 122) | BI 10 mg QD (n = 122) | BI 25 mg QD (n = 123) | Placebo (n = 120) | Total (n = 610) |
|---|---|---|---|---|---|---|
Male | 55 (44.7) | 60 (49.2) | 56 (45.9) | 59 (48.0) | 56 (46.7) | 286 (46.9) |
Mean (SD) age, years | 72.3 (7.5) | 72.5 (8.2) | 74.4 (6.9) | 72.9 (7.7) | 72.4 (7.9) | 72.9 (7.7) |
Race | ||||||
American Indian or Alaska Native | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Asian | 11 (8.9) | 10 (8.2) | 12 (9.8) | 14 (11.4) | 11 (9.2) | 58 (9.5) |
Black or African American | 10 (8.1) | 5 (4.1) | 4 (3.3) | 3 (2.4) | 8 (6.7) | 30 (4.9) |
Native Hawaiian or Pacific Islander | 0 (0.0) | 2 (1.6) | 1 (0.8) | 1 (0.8) | 2 (1.7) | 6 (1.0) |
White | 97 (78.9) | 103 (84.4) | 100 (82.0) | 102 (82.9) | 93 (77.5) | 495 (81.1) |
Multiple | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Missing | 5 (4.1) | 2 (1.6) | 5 (4.1) | 3 (2.4) | 6 (5.0) | 21 (3.4) |
Mean (SD) body mass index, kg/m2 | 26.7 (4.8) | 26.8 (5.5) | 26.3 (4.3) | 26.0 (4.5) | 26.7 (5.6) | 26.5 (4.9) |
Disease severity | ||||||
Mild | 88 (71.5) | 88 (72.1) | 88 (72.1) | 88 (71.5) | 87 (72.5) | 439 (72.0) |
Moderate | 35 (28.5) | 34 (27.9) | 34 (27.9) | 35 (28.5) | 33 (27.5) | 171 (28.0) |
MMSE category on the median score | ||||||
< 22 | 58 (47.2) | 56 (45.9) | 55 (45.1) | 60 (48.8) | 58 (48.3) | 287 (47.0) |
≥ 22 | 65 (52.8) | 66 (54.1) | 67 (54.9) | 63 (51.2) | 61 (50.8) | 322 (52.8) |
Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (0.8) | 1 (0.2) |
Baseline cholinesterase inhibitor use | ||||||
Yes | 69 (56.1) | 78 (63.9) | 77 (63.1) | 76 (61.8) | 81 (67.5) | 381 (62.5) |
APOE4positive,N(%) | 64 (52.0) | 48 (39.3) | 77 (63.1) | 62 (50.4) | 52 (43.3) | 303 (49.7) |